Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration

Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selatogrel and Cenerimod, Both With Blockbuster Revenue PotentialIncludes Future Optionality to Expand...

Related Keywords

Hyderabad ,Andhra Pradesh ,India ,Switzerland ,New York ,United States ,South Korea ,Shanghai ,China ,New York University ,Columbia University ,Japan ,America ,Swiss ,Scotta Smith ,Anca Askanase ,Jean Paul Clozel ,Philippe Martin ,Deepakl Bhatt ,Linkedin ,Idorsia Ltd ,Lupus Center ,Viatris Inc ,Swiss Exchange ,Nasdaq ,Youtube ,Prnewswire Viatris Inc ,Instagram ,Productive Drug Development Team ,York University ,Exchange Commission ,Twitter ,Expands Viatri Portfolio ,Innovative Assets ,Immediately Adding Two Phase ,Both With Blockbuster Revenue ,Future Optionality ,Expand Collaboration With Additional Innovative ,Viatri Financial Strength ,Worldwide Operational Infrastructure Withidorsia ,Highly Productive Drug Development Team ,Structure Reinforces Viatri Disciplined Approach ,Announces Rd Event ,Held March ,Chief Rd Officer Philippe Martin ,Paul Clozel ,Global Healthcare ,Mount Sinai ,Rheumatology Clinical ,Selatogrel Outcome Study ,Acute Myocardial Infarction ,Special Protocol Assessment ,North America ,Private Securities Litigation Reform Act ,Fair Disclosure ,Markets ,